Medical Industry Feature   /     Emerging Biomarker Landscape in Gastro/Gastroesophageal Cancer

Subtitle
Duration
00:00:00
Publishing date
2024-11-12 00:00
Link
https://reachmd.com/programs/medical-industry-feature/emerging-biomarker-landscape-in-gastrogastroesophageal-cancer/15431/
Contributors
Enclosures
https://reachmd.com/programs/medical-industry-feature/emerging-biomarker-landscape-in-gastrogastroesophageal-cancer/15431/podcast/52772.mp3?partner=itunes
audio/mpeg

Shownotes

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Steven Maron, MD, MSc

Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it’s important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient’s treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven Maron, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York.

References:

  1. The Cancer Genome Atlas Network. Nature. 2014;513:202-209.
  2. Fontana E, et al. Ther Adv Med Oncol. 2016;8:113-125.
  3. Yang B, et al. J Exp Clin Cancer Res. 2019;38:283.
  4. American Cancer Society. https://www.fightcancer.org/sites/default/files/Improving%20Access%20to%20Biomarker%20Testing_FINAL.pdf. Accessed July 20, 2024.
  5. Catenacci DVT, et al. Future Oncol. 2019;15:2073-2082.

©2024 Amgen Inc. All rights reserved. USA-OCF-82400 9/24